← All Alt5 Sigma CORP filings

Alt5 Sigma CORP 10-K annual reports

Annual reports — audited financials, the full risk-factor list, and management’s account of the year.

NASDAQ
ALTS
Alt5 Sigma CORP
10-K/A: ALT5 Sigma Corp. Files Amended 10-K with Clawback Policy
ALT5 Sigma Corporation has filed an amendment to its 2025 Annual Report on Form 10-K, primarily to include its Compensation Recoupment (Clawback) Policy.
NASDAQ
ALTS
Alt5 Sigma CORP
10-K/A: ALT5 Sigma Adopts Executive Compensation Clawback Policy
ALT5 Sigma Corporation filed an amendment to its annual report to include a new policy for recovering erroneously awarded executive compensation, ensuring compliance with Nasdaq and SEC rules.
NASDAQ
ALTS
Alt5 Sigma CORP
10-K: ALT5 Sigma Corporation Reports Mixed Results in 10-K Filing: Fintech Growth Offsets Continued Losses
ALT5 Sigma Corporation's 10-K filing reveals a year of transition, marked by fintech expansion and ongoing efforts to address financial reporting weaknesses.
NASDAQ
ALTS
Alt5 Sigma CORP
10-K/A: ALT5 Sigma Corporation Files Amendment to 2023 Annual Report to Correct Exhibit Dates
ALT5 Sigma Corporation files an amendment to its 2023 annual report to correct misdated exhibits related to Sarbanes-Oxley Act certifications.
NASDAQ
ALTS
Alt5 Sigma CORP
10-K: JanOne Inc. 10-K Filing: Transitioning to Clinical-Stage Biopharma, Disposing of Legacy Recycling Business
JanOne Inc.'s 10-K filing details its strategic shift to a clinical-stage biopharmaceutical company, highlighted by the acquisition of Soin Therapeutics and the divestiture of its legacy recycling business.